Li Ying, Yang Chunmei, Mao Liping, Wang Jinghan, Li Chenying, Qian Wenbin
Department of Hematology, the First Affiliated Hospital of Zhejiang University Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China.
Medicine (Baltimore). 2017 Sep;96(39):e8091. doi: 10.1097/MD.0000000000008091.
Angioimmunoblastic T-cell lymphoma (AITL) is a major subtype of peripheral T-cell lymphoma (PTCL). Due to its low incidence, the characteristics of AITL are still not well understood. The prognostic evaluation of this disease has not been established.We retrospectively analyzed 52 patients with newly diagnosed AITL in China between January 2008 and September 2016.Among these patients, the median age at diagnosis was 62 (40-83) and 58% (30/52) of the patients were older than 60 years. Thirty-five patients were male, accounting for 67.3% of the whole. Among these, 90% (47/52) of the diagnoses were estimated at advanced stage. A total of 25 (48%) patients were scored >1 by the ECOG performance status. Systemic B symptoms were described in 34 (65%) patients. When evaluated by International Prognostic Index (IPI), 81% were scored >2, and 77% got >1 score according to the prognostic index for PTCL (PIT) upon diagnosis. The 3-year progression-free survival (PFS) was 44% and the 3-year overall survival (OS) rate was 52%. IPI and PIT scores could not be effectively applied to stratify those AITL patients into subgroups. Our multivariate analysis results found that the elevated serum C-reactive protein (CRP) level was an independent adverse factor to the OS of the AITL patients.Patients with AITL had a poor outcome. The serum level of CRP may be applied as an independent prognostic factor for AITL.
血管免疫母细胞性T细胞淋巴瘤（AITL）是外周T细胞淋巴瘤（PTCL）的一种主要亚型。由于其发病率低，AITL的特征仍未得到充分了解。该疾病的预后评估尚未确立。我们回顾性分析了2008年1月至2016年9月期间在中国新诊断的52例AITL患者。在这些患者中，诊断时的中位年龄为62岁（40 - 83岁），58%（30/52）的患者年龄超过60岁。35例患者为男性，占全部患者的67.3%。其中，90%（47/52）的诊断为晚期。共有25例（48%）患者的东部肿瘤协作组（ECOG）体能状态评分为>1分。34例（65%）患者出现全身B症状。根据国际预后指数（IPI）评估，81%的患者评分为>2分，根据PTCL的预后指数（PIT），77%的患者在诊断时评分为>1分。3年无进展生存期（PFS）为44%，3年总生存期（OS）率为52%。IPI和PIT评分不能有效地将这些AITL患者分层为亚组。我们的多因素分析结果发现，血清C反应蛋白（CRP）水平升高是AITL患者OS的独立不良因素。AITL患者预后较差。血清CRP水平可作为AITL的独立预后因素。
